৳ 600/unit
Pack: ৳ 18,000
৳ 600/unit
Pack: ৳ 18,000
At a glance
Lenvatinib Mesylate is an oral receptor tyrosine kinase inhibitor used in the treatment of thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma.
Indications
- Differentiated thyroid cancer (DTC) - locally recurrent or metastatic, radioactive iodine-refractory
- Renal cell carcinoma (RCC) - in combination with Everolimus, following prior anti-angiogenic therapy
- Hepatocellular carcinoma (HCC) - first-line treatment for unresectable HCC
- Endometrial carcinoma - in combination with Pembrolizumab (non-MSI-H or dMMR)
Pharmacology
Lenvatinib inhibits the kinase activities of VEGFR1-3, FGFR1-4, PDGFR-α, KIT, and RET, blocking angiogenesis, tumor growth, and cancer progression.
Dosage
Differentiated Thyroid Cancer (DTC): 24 mg PO once daily
Renal Cell Carcinoma (RCC): 18 mg PO once daily + Everolimus 5 mg
Hepatocellular Carcinoma (HCC): ≥60 kg: 12 mg; <60 kg: 8 mg PO once daily
Endometrial Carcinoma: 20 mg PO once daily + Pembrolizumab 200 mg IV every 3 weeks
Severe Renal/Hepatic Impairment: DTC: 14 mg; RCC/Endometrial: 10 mg once daily
Side effects
Common Side Effects:
- Hypertension
- Diarrhea
- Fatigue
- Joint and muscle pain
- Nausea and vomiting
- Decreased appetite
- Weight loss
- Skin rash and peeling
- Mouth sores
- Cough, hoarseness
- Proteinuria
- Hypocalcemia
- QT interval prolongation
Use in pregnancy
Use in Pregnancy: Lenvatinib may be unsafe during pregnancy; animal studies have shown harmful effects on the fetus. Use effective contraception for at least 30 days after the last dose.
Precautions & warnings
- Control blood pressure; monitor after 1 week, then every 2 weeks for first 2 months, then monthly
- Monitor liver function every 2 weeks for first 2 months, then monthly
- Monitor for proteinuria
- Manage diarrhea with fluids; inform your doctor
- Risk of severe hemorrhage (tumor invasion/infiltration)
- Withhold for at least 6 days prior to surgery
- Can cause fetal harm during pregnancy
Overdose effects
Overdose treatment: observation and supportive measures; death due to multiorgan dysfunction occurred with 120 mg single dose. Dialysis is not expected to be effective.
Storage conditions
Store below 30°C in a dry place, protected from light; keep out of reach of children.